Nerandomilast in Patients with Progressive Pulmonary Fibrosis
New England Journal of Medicine · 12.06.2025 · 392 (22) · 2203-2214
DOI: 10.1056/nejmoa2503643 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.06.2025. Verfasst von Toby M Maher und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Pulmonary Fibrosis, Antifibrotic Agents, Immunomodulating Agents. Die Arbeit wurde bisher 241-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: The FIBRONEER-ILD trial was supported by Boehringer Ingelheim International GmbH..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
- Section of Inflammation, Repair, and Development, National Heart and Lung Institute, Imperial College London, London.
- Division of Rheumatology, McGovern Medical School, UTHealth Houston, Houston.
- Clinical Research Center, Mihara General Hospital, Saitama, Japan.
- Nippon Medical School, Tokyo.
- National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Unité Mixte de Recherche 754, European Reference Network for Rare Respiratory Dise…
ORCID-Profile: Vincent Cottin, Marlies S Wijsenbeek
Förderung
- The FIBRONEER-ILD trial was supported by Boehringer Ingelheim International GmbH.
Zitieren
APA
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A. M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., Clerisme-Beaty, E., Coeck, C., Gu, H., Ritter, I., Schlosser, A., Stowasser, S., Voss, F., Weimann, G., Zoz, D. F., …, & FIBRONEER-ILD Trial Investigators (2025). Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine, 392(22), 2203-2214. https://doi.org/10.1056/nejmoa2503643
Vancouver
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine. 2025;392(22):2203-2214. doi:10.1056/nejmoa2503643
BibTeX
@article{Maher2025,
author = {Maher, Toby M and Assassi, Shervin and Azuma, Arata and Cottin, Vincent and Hoffmann-Vold, Anna-Maria and Kreuter, Michael and Oldham, Justin M and Richeldi, Luca and Valenzuela, Claudia and Wijsenbeek, Marlies S and Clerisme-Beaty, Emmanuelle and Coeck, Carl and Gu, Hui and Ritter, Ivana and Schlosser, Arno and Stowasser, Susanne and Voss, Florian and Weimann, Gerrit and Zoz, Donald F and Martinez, Fernando J and FIBRONEER-ILD Trial Investigators, FIBRONEER-ILD Trial Investigators},
title = {Nerandomilast in Patients with Progressive Pulmonary Fibrosis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {22},
pages = {2203--2214},
doi = {10.1056/nejmoa2503643}
}
EUVIMED